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Abstract
Background Resection of a residual retroperitoneal tumor
mass (RRRTM) is standard procedure after combination
chemotherapy for metastatic nonseminomatous testicular
germ cell tumors (NSTGCT).
Methods At the University Medical Center Groningen, 79
consecutive patients with disseminated NSTGCT were
treated with cisplatin combination chemotherapy between
2005 and 2007. Laparoscopic RRRTM was performed for
patients with RRTM located less than 5 cm ventrally or
laterally from the aorta or the vena cava. The 29 patients
who fulﬁlled the criteria had a median age of 25 years
(range, 16–59 years). The stages of disease before che-
motherapy treatment according to the Royal Marsden
classiﬁcation were 2A (n = 6, 21%), 2B (n = 14, 48%),
2C (n = 3, 10%), and 4 with a lymph node status of N2
(n = 6, 21%).
Results The median duration of laparoscopy was 198 min
(range, 122–325 min). The median diameter of the RRTM
was 21 mm (range, 11–47 mm). Laparoscopic resection
was successful for 25 patients (86%). Conversion was
necessary for three patients (10%): two due to bleeding and
one because of obesity. One nonplanned hand-assisted
procedure (3%) also had to be performed. Histologic
examination of the specimens showed ﬁbrosis or necrosis
in 12 patients (41%), mature teratoma in 16 patients (55%),
and viable tumor in 1 patient (3%). The median hospital
stay was 1 day (range, 1–6 days). During a median follow-
up period of 47 months (29–70 months), one patient
experienced an early relapse (1 month after the end of
treatment) (4%).
Conclusion For properly selected patients, laparoscopic
resection of RRTM is an improvement in the combined
treatment of disseminated NSTGCT and associated with a
short hospital stay, minimal morbidity, rapid recovery, and
a neat cosmetic result. Long-term data to prove oncologic
efﬁcacy are awaited.
Keywords Nonseminomatous  Testicular germ cell
tumor  Residual retroperitoneal tumor mass
Treatment for nonseminomatous testicular germ cell
tumors (NSTGCT) has developed enormously during the
past 30 years, leading to an improved prognosis with an
overall 10-year survival rate of almost 90% [1]. Dissemi-
nated disease is treated with cisplatin-based polychemo-
therapy that comprises three or four courses of bleomycin,
etoposide, and platinum (BEP) according to the Interna-
tional Germ Cell Consensus Classiﬁcation (IGCCC)
prognosis group [2, 3].
Surgical resection is the gold standard for managing
postchemotherapy residual retroperitoneal masses in
advanced NSTGCT. The aim of surgery is to resect the
residual retroperitoneal tumor mass (RRTM) and other
residual disease localizations such as lung metastases
[4, 5]. The policy with regard to the extent of surgery for
residual masses after chemotherapy is a subject of ongoing
discussion with a surgical spectrum that ranges from
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and Other Interventional Techniques excision of only visible abnormal masses [6, 7] to full
bilateral retroperitoneal lymph node dissection (RPLND)
[8, 9]. Proponents of a full bilateral RPLND state that
patients with advanced NSTGCT are at high risk for tumor
in lymph nodes not included in modiﬁed RPLND because
areas of teratoma or carcinoma are difﬁcult to visualize
intraoperatively. However, the literature conﬁrms that
modiﬁed postchemotherapy RPLND for well-deﬁned
residual masses is a safe surgical and oncologic procedure
with less morbidity [7, 10].
After chemotherapy, mature teratoma and viable resid-
ual tumor are the main arguments for surgery. An alter-
native approach to surgery can be observation of patients
with NSTGCT after systemic chemotherapy. Models for
predicting postchemotherapy residual mass histology have
been proposed to determine the patients for whom surgery
should be considered [11, 12]. Noninvasive attempts have
been made to predict ‘‘reliably’’ the viability of residual
tumor tissue after chemotherapy using magnetic resonance
imaging (MRI) and, more recently, positron emission
tomography (PET) [13]. Nevertheless, because reliable
predictions about necrosis, ﬁbrosis, mature teratoma, or
viable tumor tissue in the residual metastases cannot be
made, adjuvant surgery with resection of residual disease
still is indicated.
Traditionally, open full-template non-nerve-sparing
RPLND was the standard practice. This approach was
associated with complications related to invasive surgery,
particularly damage to the sympathetic ganglia, hypogas-
tric nerves, or postganglionic nerve ﬁbers. These compli-
cations were responsible for sexual morbidity, mainly
anejaculation and erectile disturbances [14]. Currently, the
morbidity is low, and preservation of sexual and ejacula-
tory function is highly reliable with either a template- or
nerve-sparing complete RPLND, especially in high-volume
centers [15]. The median postoperative hospital stay is
6 days [16].
Higher morbidity with open RPLND and the general
beneﬁts of laparoscopy such as decreased blood loss, less
pain, better cosmetic results, and a shorter postoperative
hospital stay have led to the introduction of laparoscopic
RPLND. On a modest scale, laparoscopic RPLND is per-
formed primarily for the staging and possible treatment of
testicular cancer, mainly in stage 1 disease [17–19]. With
further reﬁnement of laparoscopic techniques, several
centers also have described the beneﬁts of the laparoscopic
procedure for stage 2 disease after completion of chemo-
therapy [20–26].
At the University Medical Center Groningen (UMCG),
the feasibility of resecting RRTM laparoscopically was
explored and evaluated as a minimally invasive surgical
technique applied in the ﬁeld of adjuvant surgery in the
combined treatment of testicular cancer.
Materials and methods
From October 2004 to August 2007, 79 consecutive
patients with disseminated NSTGCT were treated using
cisplatin-based combination chemotherapy at UMCG.
Before chemotherapy, the patients were staged according
to the Royal Marsden classiﬁcation system based on spiral
computed tomographic (CT) ﬁndings of the abdomen as
well as on chest and tumor marker analysis. Patients
received three or four courses of BEP depending on their
IGCCC classiﬁcation [2, 3].
After completion of chemotherapy, when the patients
had achieved complete biochemical remission (90%), they
were restaged with a spiral CT of the abdomen and chest.
Of the 79 patients, 53 (67%) showed a complete bio-
chemical response with residual disease. Afterward, 45
patients (57%) had surgery, primarily resection of a
residual retroperitoneal tumor mass (RRRTM) (51%).
Table 1 summarizes the baseline characteristics and
outcome data for all 79 consecutive patients. Eight patients
with residual disease and a complete response (10%) did
not undergo surgery because of extended disease in mul-
tiple organs (n = 6), mediastinal disease (n = 1), or irre-
sectable massive retroperitoneal residual disease (n = 1).
Patient selection for laparoscopic RRRTM was based on
the size and location of the residual tumor. Patients with a
residual retroperitoneal tumor mass with a diameter smaller
than 50 mm shown on CT and located ventrally or laterally
from the aorta or vena cava were candidates for laparo-
scopic resection of these abnormalities. Retroperitoneal
tumor masses posterior to the great vessels were not can-
didates for laparoscopic resection.
On the basis of these selection criteria, 29 patients with a
median age of 25 years (range, 16–59 years) underwent an
adjunctive laparoscopic RRRTM. The characteristics of
these patients are summarized in Table 2. The primary
tumor location was in the left testicle of 16 patients (55%)
and in the right testicle of 13 patients (45%). The median
follow-up period in this study was 47 months (range,
29–70 months). During the same period, 11 patients
underwent conventional laparotomy for RRRTM (Fig. 1).
Eight patients had residual retroperitoneal disease too large
for laparoscopic resection, and for three patients, a lapa-
roscopic procedure was not opportune because of the tumor
location.
Laparoscopic procedure
Preoperatively, no intestinal preparation was done, and no
prophylactic antibiotics were administered. Laparoscopic
resection was performed by experienced laparoscopic sur-
gical oncologists. The patients were placed supine with
both legs abducted in the ‘‘French’’ position (also called the
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123lithotomy position) or in a half-right lateral position
depending on the site of the RRTM.
In the case of a predominant pericaval residual tumor
mass, the patients underwent surgery in the French posi-
tion. Periaortic and left-sided masses were resected with
patients in the half-right lateral position. Patients with
bilateral RRTM were again placed in the French position.
Pneumoperitoneum was created using an open technique,
and the ﬁrst 10-mm blunt tip trocar was situated paraum-
bilically (for the camera). Additionally, a 5-mm trocar was
placed in the suprapubic region and a 10-mm trocar in the
left lower abdomen. Another 5-mm trocar was inserted into
the epigastrium (Fig. 2).
Dissection was performed using the Harmonic ultra-
sonic cutting device (Ethicon-Endosurgery, Cincinnati,
OH, USA). During the laparoscopic approach, the colon
was mobilized to expose the aorta, the vena cava, or both.
The anatomic landmarks were the renal vein, the ureter,
and the iliac vessels. Care was taken to avoid the lumbar
vessels in the retroaortic region, with the aim to prevent
autonomic nerve damage.
After exposure of the retroperitoneum and identiﬁcation
of the RRTM, extension of the surgical resection consisted
of excising the RRTM only without unilateral dissection
according to templates. An EndoCatch (Covidien, Man-
ﬁeld, MA, USA) was used to remove the surgical speci-
men. Intraoperative frozen section analysis of the specimen
was not performed. No drains were used. The aim was to
perform non-hand-assisted procedures. Conversion was
performed when complications arose or when the surgical
oncologist had the impression that the RRTM could not be
removed completely using laparoscopy.
After laparoscopic resection, the patients were followed
in the same manner as patients after conventional resection.
A strict follow-up protocol according to European Society
for Medical Oncology guidelines was carried out by the
medical oncologist. This protocol included a monthly
clinical assessment and tumor marker determination during
the ﬁrst postoperative year, followed by a gradually
tapering schedule (every 2 months the second year, every
3 months the third year, every 6 months the fourth year,
then annually thereafter). A CT scan of the chest and
abdomen was performed in the case of clinical or bio-
chemical signs of recurrence or for patients who were
marker negative at the initial presentation of disseminated
disease. Operative time, complications, transfusion rate,
conversion to open surgery, and duration of hospital stay
were analyzed.
Results
All 29 patients included in the laparoscopic treatment
group had a biochemical complete remission after che-
motherapy. Polychemotherapy elicited a reduction of the
retroperitoneal metastases with a mean factor of 0.6,
resulting in a median postchemotherapy tumor size of
21 mm (range, 11–47 mm) (Table 2). In almost two thirds
of the patients, the residual tumor was located in the latero-
aortic region. The median interval between the last chemo-
therapy course and the laparoscopic resection of RRTM
was 3 months (range, 1–6 months).
For 25 patients (86%), the laparoscopic procedure could
be conducted as planned. For 3 patients (10%), conversion
to open surgery was necessary due to slight bleeding from
the common iliac artery, larger bleeding from the aorta,
and the impossibility of creating a good exposure in an
obese patient. In another patient (3%), the initial plan was
changed because extreme obesity prevented the creation of
a window sufﬁciently large for laparoscopic exploration,
Table 1 Patient baseline characteristics and outcome data for all 79
consecutive nonseminomatous testicular germ cell cancer patients
with disseminated disease treated using cisplatin-based chemotherapy
at the University Medical Center Groningen (UMCG) between
October 2004 and August 2007
Median age: years (range) 29 (18–63)
Stage of disease according
to Royal Marsden: n (%)
Stage 2: 43 (54)
Stage 3: 4 (5)
Stage 4:31 (39)
Unknown: 1 (1)
Prognosis (IGCCC): n (%)
Good 46 (58)
Intermediate 22 (28)
Poor 10 (13)
Unknown 1 (1)
Tumor response after chemotherapy: n (%)
Complete biochemical response 71 (90)
Without residual disease 18 (23)
With residual disease 53 (67)
No surgery of residual disease 8 (10)
Surgery of residual disease 45 (57)
Retroperitoneal 40 (51)
Lungs 5 (6)
No normalization of tumor markers 5 (6)
Biochemical relapse within 1 month 1 (1)
No completion of chemotherapy 2 (3)
Outcome/survival status: n (%)
No evidence of disease 68 (86)
Alive with disease 4 (5)
Died of disease 6 (8)
Died of other causes 1 (1)
Median follow-up after
chemotherapy: months (range)
For all 79 patients 52 (3–75)
For 72 patients (excluding 7 patients who died) 53 (21–77)
460 Surg Endosc (2012) 26:458–467
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123and a hand-assisted laparoscopic resection of the tumor
was performed. The only minor perioperative complication
encountered was an injury to the testicular vein at the left
side, which was managed laparoscopically with clips.
The median duration of surgery for the 29 patients,
including positioning of the patient, was 198 min (range,
122–325 min). When the three patients who had conver-
sion to laparotomy and the one patient who underwent a
hand-assisted procedure were excluded, the median dura-
tion of a successful laparoscopic resection was 195 min
(range, 122–325 min). The estimated blood loss was min-
imal (\50 ml), except for the converted patient with
bleeding from the common iliac artery who did not need
blood transfusion and the converted patient with bleeding
from the aorta who lost up to 1,500 ml of blood.
Fig. 1 Flowchart of patients with disseminated testicular cancer
receiving polychemotherapy (October 2004–August 2007)
Fig. 2 Operative technique. Positioning of patient (‘‘French’’ posi-
tion) and team
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123The median postoperative hospital stay was only 1 day
(range, 1–6 days). The longest postoperative hospital stay
(6 days) was experienced by the patient who had to
undergo conversion due to injury of the aorta. During
preparation of the two residual tumor masses from the
aorta, a large bleeding occurred. Laparoscopy was quickly
converted to a laparotomy, and the diathermic injury to the
aorta was managed with two sutures. This procedure
required a total operative time of 149 min.
No postoperative infections occurred. One short-term
postoperative complication (3%) included a massive chy-
lous ascites which could not be treated conservatively.
After 4 months, laparoscopic exploration showed visible
leakage from a lymph vessel, which was coagulated suc-
cessfully with argon diathermia and clipped. One patient
had anejaculation after laparoscopic RRRTM.
Histologic examination showed necrosis or ﬁbrosis in 12
patients (41%) and teratoma in 16 patients (55%). In one
patient (3%), a radically resected viable tumor was found.
Preoperatively, this patient received three courses of BEP,
and after complete laparoscopic RRRTM, no additional
chemotherapy courses were given.
During the median follow-up period of 47 months
(mean, 46 months; range, 29–70 months), one short-term
local recurrence was experienced by a 34-year-old man in
the good risk prognosis group who had mature, immature
teratoma and seminoma elements in his right-sided primary
tumor. This man received three courses of BEP. Polyche-
motherapy resulted in a biochemical complete remission
and was followed by a laparoscopic RRRTM. Residual
tumor masses were located on the left side next to the aorta
and between the aorta and the vena cava. Histology showed
ﬁbrosis. The man’s tumor markers were slightly elevated
1 month after laparoscopy and 6 months after completion
of chemotherapy. A CT scan showed recurrence between
the aorta and the vena cava (Fig. 3). Additional polyche-
motherapy (paclitaxel, ifosfamide, and cisplatin) was
administered, and the patient achieved a complete
response, both biochemically and radiologically. A lapa-
rotomy with formal template dissection on both sides was
performed. Histology of the specimen showed ﬁbrosis. No
signs of recurrence were detected 41 months after the
man’s last surgery.
Discussion
Laparoscopic RPLND was ﬁrst described in 1992 for a
patient with stage 1 NSTGCT [17]. With further develop-
ment of laparoscopic techniques and experience perform-
ing them, laparoscopic RPLND was introduced in several
specialized centers for the staging and treatment of mainly
low-stage testicular cancer using the same boundaries of
dissection as with an open approach. Table 3 summarizes
the results reported by these centers [20–26]. The results
show that the laparoscopic approach is feasible, with
minimal morbidity, rapid recovery, and a neat cosmetic
result. However, long-term oncologic results and equiva-
lence of the conventional procedure with laparoscopic
RRRTM are not fully established.
At UMCG, laparoscopic RPLND has been performed
since 2005 for well-selected cases. Two thirds of the
patients with RRTM appear to be candidates for laparo-
scopic resection RRTM.
The current study aimed to investigate our results for
laparoscopic resection of RRTM, which was performed
successfully for 11- to 47-mm masses in 25 of the 29
selected patients. The postoperative complication rate was
7% due to postchemotherapy chylous ascites after RPLND,
a not unusual complication with an incidence of 2% [27],
and anejaculation experienced by one patient. The median
hospital stay was 1 day. In addition, neat cosmetic results
were achieved.
During the same study period, 11 patients treated at
UMCG with cisplatin-based polychemotherapy for dis-
seminated NSTGCT did not fulﬁll the laparoscopic inclu-
sion criteria and were scheduled for conventional surgery
consisting of laparotomy with RRRTM. The median post-
operative stay for these 11 patients who underwent a lap-
arotomy for RRTM was 6 days (range, 2–9 days), which is
comparable with the median hospital stay after laparotomy
reported in the 1980s [16].
As mentioned earlier, four procedures (14%) could
not be performed (completely) according to plan. The
Fig. 3 Abdominal computed tomography (CT) scan of retroperito-
neal recurrence
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123conversion rate for seven reported series varied from 0 to
75% and was 14% (4 patients) in the current series
(Table 3)[ 20–26]. These four conversions included a
nonplanned hand-assisted laparoscopic procedure and a
laparotomy because of technical difﬁculties based on
obesity of the patients. Two other conversions to a con-
ventional laparotomy were required due to bleedings,
which included one slight bleeding of the iliac artery and a
larger bleeding from the aorta.
Residual retroperitoneal tumor masses are sometimes
extensively attached to surrounding tissues, making a good
resection extremely difﬁcult to achieve. This can explain
the occurrence of bleedings, such as the bleeding from the
aorta. This risk of a bleeding possibly is higher with lap-
aroscopic procedures than with open procedures, so ade-
quate patient selection with evaluation of the tumor
characteristics is important. In most cases, laparoscopic
techniques are sufﬁcient for handling bleedings, and con-
version is not needed.
In the current study, one bleeding of the testicular vein
could be managed laparoscopically. The patient was dis-
charged from the hospital 1 day postoperatively. In another
study, 9 of 59 patients (43 stage 2B, 16 stage 2C) experi-
enced bleeding during laparoscopy not requiring conver-
sion [23].
In the series of Steiner et al. [22], 68 patients underwent
laparoscopy after two or three courses of chemotherapy
without the need for any conversion. However, these
authors did convert 2.4% of the stage 1 patients. These
patients had not received preoperative chemotherapy.
In a small series by Rassweiler et al. [20], six (75%) of
eight patients with stage 2C disease who underwent post-
chemotherapy laparoscopy had conversion to a laparotomy
because of desmoplastic reaction around the aorta and the
vena cava as a result of chemotherapy [28, 29]. Perm-
pongkosol et al. [24] had to convert procedures due to
vascular injury in 2 (12.5%) of 16 patients who had
received three or four courses of chemotherapy (Table 3).
The median duration of the laparoscopic procedure in the
current series was 198 min, compared with 216–348 min
described in literature. Furthermore, the median postopera-
tive hospital stay was 1 day compared with median hospital
staysrangingfrom2to8.2 daysinotherlaparoscopicseries.
Theseotherseriesalsoincludedpatientswhohadconversion
to a laparotomy, thus explaining the discrepancy with our
results.
Currently, very few institutions have reported laparo-
scopic RRRTM after chemotherapy for disseminated
NSTGCT. Our ﬁrst experience with this new technique was
favorable. The minimal morbidity, the short postoperative
hospital stay, and the neat cosmetic result are a step for-
ward in the combined treatment of testicular cancer.
Although we have achieved good results over the past
30 years with conventional RRRTM, it appears that this
also is possible with laparoscopic resection for patients
with minimal RRTM. Approximately 70% of disseminated
testicular cancer patients who require RRRTM are candi-
dates for complete laparoscopic resection based on the
current selection criteria. However, it is unknown whether
the laparoscopic procedure will result in more frequent
(short or late) relapses. In the current series, one patient
(4%) had a short-term relapse. The recurrence was located
between the vena cava and the aorta. Preoperative CT scan
images showed an RRTM located on the left side of the
aorta between the aorta and vena cava. Although this
RRTM was resected during laparoscopy, residual tissue
remained behind, causing outgrowth of viable tumor. This
relapse can be calculated as a technical failure. Short- and
long-term relapses after chemotherapy are mostly related to
incomplete resection of residual disease and also are
encountered after conventional surgery [30].
The limitation of this study is that the oncologic efﬁcacy
of the procedure remains questioned because the long-term
oncologic follow-up data are not equivalent to those for the
open procedure. In the future, after more patients have been
treated with laparoscopic resection, data will become
available with reliable relapse ﬁgures. This potential pitfall
requires prolonged and very stringent follow-up assessment
to monitor the oncologic safety of the laparoscopic resec-
tion of RRTM. It is important to perform thorough follow-
up assessment to be certain that a minimally invasive
intervention does not involve the risk of so-called extra-
template disease [31].
An overshadowing component of our study is the con-
troversy surrounding the surgical management of patients
with NSTGCT and concerns about the development of late-
relapsing abdominal teratoma [29]. Late-recurring disease
is characterized by slow growth, production of alpha-
fetoprotein, chemoresistance, and a poor prognosis [28].
Our surgical management of patients with NSTGCT con-
forms to the European guidelines for testicular cancer [27].
Although our results and those of others are favorable,
questions remain: Is laparoscopic RRRTM as complete
oncologically as an open procedure? How long should we
wait before laparoscopic RRRTM is proclaimed as the
standard, or should a randomized study be performed?
Particularly the rapid postoperative recovery, the low
morbidity, and the neat cosmetic results contribute to the
well-being of the usually young patients, most of whom
still have many years ahead of them. Whatever policy is
chosen for the treatment of patients with advanced
NSTGCT, management should take place at a referral
center with speciﬁc expertise in the treatment of testicular
cancer and an oncologic team of specialists.
Surg Endosc (2012) 26:458–467 465
123Conclusion
Laparoscopic RRRTM after chemotherapy for dissemi-
nated testicular cancer is a feasible surgical treatment
option with a short hospital stay and neat cosmetic results
for well-selected patients. Which patients are the right
candidates for laparoscopic RRRTM remains the question.
Close and long-term follow-up assessment of long-term
results with respect to tumor recurrence is obligatory.
Disclosures C ¸ig ˘dem O ¨ztu ¨rk, Robert J. van Ginkel, Ruby M. Krol,
Jourik A. Gietema, Hendrik S. Hofker, and Harald J. Hoekstra have
no conﬂicts of interest or ﬁnancial ties to disclose.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ,
Mulder NH, Willemse PH et al (2001) Improved long-term sur-
vival of patients with metastatic nonseminomatous testicular
germ cell carcinoma in relation to prognostic classiﬁcation sys-
tems during the cisplatin era. Cancer 91:1304–1315
2. International Germ Cell Cancer Collaborative Group (1997)
International Germ Cell Consensus Classiﬁcation: a prognostic
factor-based staging system for metastatic germ cell cancers.
J Clin Oncol 15:594–603
3. Huddart RA (2007) Testicular seminoma: ESMO clinical rec-
ommendations for diagnosis, treatment, and follow-up. Ann
Oncol 18(Suppl 2):ii40–ii41
4. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD
(2003) Postchemotherapy retroperitoneal surgery remains nec-
essary in patients with nonseminomatous testicular cancer and
minimal residual tumor masses. J Clin Oncol 21:3310–3317
5. Kesler KA, Kruter LE, Perkins SM, Rieger KM, Sullivan KJ,
Runyan ML, Brown JW, Einhorn LH (2011) Survival after resec-
tion for metastatic testicular nonseminomatous germ cell cancer to
the lung or mediastinum. Ann Thorac Surg 91:1085–1093
6. Ozen H, Ekici S, Sozen S, Ergen A, Tekgu ¨l S, Kendi S (2001)
Resection of residual masses alone: an alternative in surgical
therapy of metastatic testicular germ cell tumors after chemo-
therapy. Urology 57:323–327
7. Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N,
Sullivan LD (1998) Retroperitoneal lymphadenectomy for post-
chemotherapy residual masses: is a modiﬁed dissection and
resection of residual masses sufﬁcient? Br J Urol 81:295–300
8. Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ,
Bajorin D, Bosl GJ (2010) The total number of retroperitoneal
lymph nodes resected impacts clinical outcome after chemo-
therapy for metastatic testicular cancer. J Urol 75:1431–1435
9. Large MC, Sheinfeld J, Eggener SE (2009) Retroperitoneal
lymph node dissection: reassessment of modiﬁed templates. BJU
Int 104:1369–1375
10. Heidenreich A, Pﬁster D, Witthuhn R, Thu ¨er D, Albers P (2009)
Postchemotherapy retroperitoneal lymp node dissection in
advanced testicular cancer: radical of modiﬁed template resec-
tion. Eur Urol 55:217–224
11. Steyerberg EW, Keizer HJ, Fossa ˚ SD, Sleijfer DT, Toner GC,
Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Don-
ohue JP et al (1995) Prediction of residual retroperitoneal mass
histology after chemotherapy for metastatic nonseminomatous
germ cell tumor: multivariate analysis of individual patient data
from six study groups. J Clin Oncol 13:1177–1187
12. Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fossa ˚ SD,
Gerl A, de Wit R, Roberts JT, Habbema JD (2007) Predicting
retroperitoneal histology in postchemotherapy testicular germ cell
cancer: a model update and multicentre validation with more than
1000 patients. Eur Urol 51:424–432
13. Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L,
Franzius C et al (2008) [18F]Fluorodeoxyglucose pos-
itron emission tomography in nonseminomatous germ cell
tumors after chemotherapy: the German multicenter positron
emission tomography study group. J Clin Oncol 26:5930–
5935
14. van Basten JP, Jonker-Pool G, Van Driel MF, Sleijfer DT, van
der Wiel HB, Hoekstra HJ (1995) The sexual sequelae of tes-
ticular cancer. Cancer Treat Rev 21:479–495
15. Pettus JA, Carver BS, Masterson T, Stasi J, Sheinfeld J (2009)
Preservation of ejaculation in patients undergoing nerve-sparing
postchemotherapy retroperitoneal lymph node dissection for
metastatic testicular cancer. Urology 73:328–331
16. Gelderman WA, Schraffordt Koops H, Sleijfer DT, Oosterhuis
JW, Van der Heide JN, Mulder NH et al (1988) Results of
adjuvant surgery in patients with stage III and IV nonsemino-
matous testicular tumors after cisplatin-vinblastine-bleomycin
chemotherapy. J Surg Oncol 38:227–232
17. Rukstalis DB, Chodak GW (1992) Laparoscopic retroperitoneal
lymph node dissection in a patient with stage 1 testicular carci-
noma. J Urol 148:1907–1909
18. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR (2003)
Laparoscopic retroperitoneal lymph node dissection for clinical
stage I nonseminomatous germ cell testicular cancer: a long-term
update. Urology 62:324–327
19. Nielsen ME, Lima G, Schaeffer EM, Porter J, Cadeddu JA, Tuerk
I, Kavoussi LR (2007) Oncologic efﬁcacy of laparoscopic
RPLND in treatment of clinical stage I nonseminomatous germ
cell testicular cancer. Urology 70:1168–1172
20. Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken
P (1996) Laparoscopic retroperitoneal lymph node dissection for
nonseminomatous germ cell tumors: indications and limitations.
J Urol 156:1108–1113
21. Palese MA, Su LM, Kavoussi LR (2002) Laparoscopic retro-
peritoneal lymph node dissection after chemotherapy. Urology
60:130–134
22. Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch
G et al (2004) Long-term results of laparoscopic retroperitoneal
lymph node dissection: a single-center 10-year experience.
Urology 63:550–555
23. Albqami N, Janetschek G (2005) Laparoscopic retroperitoneal
lymph node dissection in the management of clinical stage I and
II testicular cancer. J Endourol 19:683–692
24. Permpongkosol S, Lima GC, Warlick CA, Allaf ME, Varkarakis
IM, Bagga HS et al (2007) Postchemotherapy laparoscopic ret-
roperitoneal lymph node dissection: evaluation of complications.
Urology 69:361–365
25. Maldonado-Valadez R, Schilling D, Anastasiadis AG, Sturm W,
Stenzl A, Corvin S (2007) Postchemotherapy laparoscopic ret-
roperitoneal lymph node dissection in testis cancer patients.
J Endourol 21:1501–1504
26. Calestroupat JP, Sanchez-Salas R, Cathelineau X, Rozet F,
Galiano M, Smyth G et al (2009) Postchemotherapy laparoscopic
retroperitoneal lymph node dissection in nonseminomatous germ
cell tumor. J Endourol 23:645–650
466 Surg Endosc (2012) 26:458–467
12327. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M,
Pettaway CA et al (2006) Chylous ascites after postchemotherapy
retroperitoneal lymph node dissection: review of the M.
D. Anderson experience. J Urol 176(4 Pt 1):1463–1467
28. Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A,
Huddart RA (2002) Late recurrence in 1263 men with testicular
germ cell tumors. Multivariate analysis of risk factors and
implications for management. Cancer 95:520–530
29. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn
LH (1995) Late relapse of testicular cancer. J Clin Oncol 13:
1170–1176
30. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ,
Bosl GJ et al (2008) Clinical outcome and predictors of survival
in late relapse of germ cell tumor. J Clin Oncol 26:5524–5529
31. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ
et al (2007) Incidence of metastatic nonseminomatous germ cell
tumor outside the boundaries of a modiﬁed postchemotherapy
retroperitoneal lymph node dissection. J Clin Oncol 25:
4365–4369
Surg Endosc (2012) 26:458–467 467
123